More harm than good: The case against using antipsychotic drugs to prevent severe mental illness

Bentall, Richard P.; Morrison, Anthony P.

doi:10.1080/09638230020023723

Cited by 86 publications

(64 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, such practices raise a number of 'human rights' issues regarding the potential of exposing people to a psychiatric career, the inherent uncertainties regarding prognosis and the administration of drugs with potentially harmful side-effects to people who may not go on to develop psychosis (Bentall and Morrison, 2002). Whilst it is probably undeniable that anti-psychotics may benefit significant numbers of people by reducing unwanted and distressing symptoms, policy guidelines which rest on the presumed necessity and primacy of anti-psychotic medications have increasingly been criticised.…”

Section: The Treatment Frameworkmentioning

confidence: 99%

Psychosis and Human Rights: Conflicts in Mental Health Policy and Practice

Spandler

Calton

2009

Social Policy & Society

View full text Add to dashboard Cite

show abstract

Section: The Treatment Frameworkmentioning

confidence: 99%

Psychosis and Human Rights: Conflicts in Mental Health Policy and Practice

Spandler

Calton

2009

Social Policy & Society

View full text Add to dashboard Cite

show abstract

“…'Wrongful' identification might expose young people to unnecessary labelling and potentially hazardous pharmacological treatments [21] and use of a 'psychosis' related label could potentially obstruct a patient's communicative interactions with others [22,23]. A better understanding of the presentation and characteristics of adolescents with a potential ARMS is thus crucial to informing the approach of mental health services to affected individuals.…”

Section: Introductionmentioning

confidence: 99%

The ‘At-Risk Mental State’ for Psychosis in Adolescents: Clinical Presentation, Transition and Remission

Welsh

Tiffin

2013

Child Psychiatry Hum Dev

View full text Add to dashboard Cite

. (2014) 'The 'At-risk mental state' for psychosis in adolescents : clinical presentation, transition and remission.', Child psychiatry and human development., 45 (1). pp. 90-98.Further information on publisher's website:http://dx.doi.org/10.1007/s10578-013-0380-z Publisher's copyright statement:The nal publication is available at Springer via http://dx.doi.org/10.1007/s10578-013-0380-z.Additional information: Use policyThe full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-pro t purposes provided that:• a full bibliographic reference is made to the original source • a link is made to the metadata record in DRO • the full-text is not changed in any way The full-text must not be sold in any format or medium without the formal permission of the copyright holders.Please consult the full DRO policy for further details. 2 Abstract:Despite increased efforts over the last decade to prospectively identify individuals at ultrahigh risk of developing a psychotic illness, limited attention has been specifically directed towards adolescent populations (<18 years). In order to evaluate how those under 18 fulfilling the operationalised criteria for an At-Risk Mental State (ARMS) present and fare over time, we conducted an observational study. Participants (N=30) generally reported a high degree of functional disability and frequent and distressing perceptual disturbance, mainly in the form of auditory hallucinations. Seventy percent (21/30) were found to fulfil the criteria for a co-morbid ICD-10 listed mental health disorder, with mood (affective; 13/30) disorders being most prevalent. Overall transition rates to psychosis were low at 24 month follow-up (2/28; 7.1%) whilst many participants demonstrated a significant reduction in psychotic-like symptoms. The generalisation of these findings may be limited due to the small sample size and require replication in a larger sample.

show abstract

“…There is a wealth of empirical evidence extending over many decades suggesting that antipsychotic medication produces significant improvements in schizophrenia symptoms (Davis 1976(Davis , 2003, prevents relapse (Hogarty 1974) and forestalls the problem of a long duration of untreated psychosis (Loebel 1992). However, there is some doubt about the consistency of these results and the nature and sustainability of longer-term outcomes (Bentall 2002;Moncrieff 2003). Over time, manifold problems emerge, such as non-concordance (Oehl 2000), treatment resistance (Kane 2007) and multifarious unpleasant, distressing and potentially life-threatening side-effects (Zarate 2001;Hennessy 2002).…”

Section: The View From Nowmentioning

confidence: 99%

Minimal-medication approaches to treating schizophrenia

Calton¹,

Spandler²

2009

Adv. psychiatr. treat

View full text Add to dashboard Cite

SummaryUK guidelines for treating people diagnosed with schizophrenia currently emphasise the primacy of antipsychotic medication, with or without psychosocially based interventions as circumstances dictate. We now see increasing calls, most notably from mental health service users, for the provision of ‘whole-person-based’, minimal-medication approaches to treating people with this diagnosis. This article is intended to locate the development of such approaches within the history of modern and pre-modern psychiatry and, in doing so, summarise the available evidence base that underpins their efficacy.

show abstract

More harm than good: The case against using antipsychotic drugs to prevent severe mental illness

Cited by 86 publications

References 20 publications

Psychosis and Human Rights: Conflicts in Mental Health Policy and Practice

Psychosis and Human Rights: Conflicts in Mental Health Policy and Practice

The ‘At-Risk Mental State’ for Psychosis in Adolescents: Clinical Presentation, Transition and Remission

Minimal-medication approaches to treating schizophrenia

Contact Info

Product

Resources

About